[go: up one dir, main page]

WO2007131280A1 - HÉMATOPOÏÈSE: RÉGULATION PAR UN GÈNE ETS (Erg) - Google Patents

HÉMATOPOÏÈSE: RÉGULATION PAR UN GÈNE ETS (Erg) Download PDF

Info

Publication number
WO2007131280A1
WO2007131280A1 PCT/AU2007/000645 AU2007000645W WO2007131280A1 WO 2007131280 A1 WO2007131280 A1 WO 2007131280A1 AU 2007000645 W AU2007000645 W AU 2007000645W WO 2007131280 A1 WO2007131280 A1 WO 2007131280A1
Authority
WO
WIPO (PCT)
Prior art keywords
erg
cell
activity
cells
hematopoietic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AU2007/000645
Other languages
English (en)
Inventor
Douglas James Hilton
Warren Scott Alexander
Benjamin Thomas Kile
Stephen John Loughran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Walter and Eliza Hall Institute of Medical Research
Original Assignee
Walter and Eliza Hall Institute of Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006902556A external-priority patent/AU2006902556A0/en
Application filed by Walter and Eliza Hall Institute of Medical Research filed Critical Walter and Eliza Hall Institute of Medical Research
Publication of WO2007131280A1 publication Critical patent/WO2007131280A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates generally to a model system providing methods and modulators suitable for use in modulating hematopoietic cell activity and for use in the treatment, prophylaxis and diagnosis of diseases or conditions associated with aberrant hematopoiesis and/or hematopoietic cell activity. Diseases or conditions including hematological disorders or genetic conditions and their sequelae including cancer and autoimmune conditions are particularly contemplated.
  • the present invention provides modified cells or a non-human animal comprising modified cells as models of aberrant hematopoiesis and/or early blood cell function wherein the activity of an ETS-related transcription factor is modified in the cell or animal relative to the activity in an unmodified cell or animal.
  • the present invention further provides agents and assays for the identification and development of agents that modulate the ets related gene (Erg) signalling pathway and Erg associated transcription suitable for use in a range of therapeutic, prophylactic and medical or veterinary applications.
  • Erg ets related gene
  • Stem cells are undifferentiated cells that give rise to a succession of mature functional cells. Regulation of these events is critical to the body's ability to respond to its environment, to heal and thrive. Dysregulation of stem cell homeostatic mechanisms can lead inter alia to cancer.
  • HSC Hematopoietic stem cells
  • HSCs are the best characterised adult stem cell population, and therefore serve as a model system in which the regulation of stem cell self renewal and differentiation may be investigated. These functions are critical to medically significant processes such as cancer and tissue regeneration.
  • the mechanisms which regulate the self-renewal of HSCs and their differentiation into multipotent progenitors are only vaguely characteristics.
  • Erg ets related gene
  • ETS Erythroblast Transformation Specific
  • 5'-GGA(A/T)-3' core recognition motifs in enhancers and promoters to activate transcription (reviewed in Sharrocks, Nat. Rev. MoI. Cell Biol, 2:827-837, 2001). It contains two distinct domains. Towards the amino-terminus is a pointed domain, the specific function of which has not been determined in Erg, but which has been associated with protein-protein interaction in other ETS family members (Kim et al, EMBOJ., 20:4173-4182, 2001; Carrere et al, Oncogene, 7(5:3261-3268, 1998).
  • ETS domain Near the carboxyl-terminus is an ETS domain, which is definitive for all ETS family members, and has a winged helix-turn-helix topology.
  • the ETS domain binds DNA via its third helix, and is critical to the function of Erg (Carrere et al, 1998 (supra)); Kodandapani et al, Nature. 350:456-460, 1996).
  • Erg may be phosphorylated at serine residues, but the mechanism and function of such phosphorylation is not yet known (Murakami et al, Oncogene, 5:1559-1566, 1993).
  • Erg is expressed in various mesodermal cells and neural crest cells during embryogenesis, T cell precursors, endothelial cells, platelets and HSCs (Vlaeminck-Guillem et al, Meek Dev., .97:331-335, 2000; Anderson et al, Development, 72(5:3131-3148, 1998; McLaughlin et al., J. Cell ScI, 112(Pt 2 ⁇ :4695-4703, 1999; Rainis et al, Cancer Res., 65:7596-7602, 2005). To date, the biological function of Erg has not been characterised.
  • Erg has also been implicated in cancer. Overexpression of Erg in NIH3T3 cells allows growth in low serum and independent of adhesion to a surface, as well as giving them the capacity to form tumours in nude mice, demonstrating that Erg is a proto-oncogene with transforming capabilities (Hart et al, Oncogene, 70:1423-1430, 1995). In 5-10% of patients with the paediatric bone cancer Ewing's sarcoma, a t(21;22) chromosomal translocation which fuses the EWS and Erg genes can be detected (Sorensen et al, Nat. Genet., 6:146-151, 1994).
  • EWS is fused with FLI-I, the most closely related paralog of Erg.
  • EWS is an RNA binding protein that can associate with the RNA polymerase II complex responsible for transcription, but its cellular function is unclear.
  • the resulting EWS-Erg fusion protein consists of the N- terminal region of EWS and the C-terminal region of Erg, including the ETS domain. Carcinogenesis is thought to occur because the EWS region confers aberrantly strong transactivation activity while the ETS domain of Erg continues to bind DNA (reviewed in Arvand et al, Oncogene, 20:5747-5754, 2001).
  • TLS/FUS is closely related to EWS and also binds to RNA and RNA polymerase II (Yang et al, MoI Cell. Biol, 20:3345-3354, 2000).
  • the TLS-Erg fusion protein is sufficient to cause a leukemic phenotype when introduced to HSCs (Pereira et al.
  • Erg has been implicated generally in physiological hematopoiesis.
  • K562 cells usually differentiate down the erythroid lineage, but can be induced to undergo megakaryocyte differentiation with phorbol esters. Erg expression was induced during such megakaryocyte differentiation.
  • the present invention provides screening methods and a class of molecules that are useful for modulating HSC activities, such as, self-renewal, homing and/or engrafting and/or modulating hematopoietic progenitor cell activity, or for the treatment and/or prophylaxis of conditions characterised by defective blood cell activity or associated with aberrant hematopoiesis.
  • a cell includes a single cell, as well as two or more cells; reference to “an agent” includes one agent, as well as two or more agents; and so forth.
  • SEQ ID NO: Nucleotide and amino acid sequences are referred to by a sequence identifier number (SEQ ID NO:).
  • the SEQ ID NOs: correspond numerically to the sequence identifiers ⁇ 400>l (SEQ ID NO:1), ⁇ 400>2 (SEQ ID NO:2), etc.
  • SEQ ID NO:1 sequence identifiers ⁇ 400>l
  • SEQ ID NO:2 sequence identifiers
  • Erg polypeptide is the expression product of Erg nucleic acid sequences.
  • the terms Erg or Erg encompass all homologs in any animal species including human homologs. Representative examples of the nucleic acid and amino acid sequences of Erg molecules are provided in the sequence listing further described in Table 1. As the skilled addressee will appreciate Erg protein in mouse is highly homologous to Erg in human (96% identity). Due to this close similarity and the close evolutionary relationship between Erg homologs, the present invention encompasses human and other mammalian species.
  • the present invention is predicated, in part, on the identification of an E26 (ETS) family transcription factor, Erg (ets related gene) as a key molecule required for early hematopoietic cell activity in a mammalian animal model.
  • ETS E26
  • Erg ets related gene
  • reduction of Erg activity in a mammalian animal resulted in animals exhibiting inter alia thrombocytopenia (low platelet (thrombocyte) counts).
  • Low platelet counts are associated with an increased risk of haemorrhage and as shown herein mammals with one mutant Erg allele showed reduced survival, internal haemorrhaging under the skin, around the joints, and skill (see Figure 14).
  • mice with one mutant Erg allele become anaemic, leukopenic and thrombocytopenic (see Figure 10).
  • mice with one mutant Erg allele become anaemic, leukopenic and thrombocytopenic (see Figure 10).
  • These mice are also profoundly deficient in the multipotent early hematopoietic progenitors that form spleen colonies indicating that without an adequate presence of Erg, hematopoiesis is disrupted through a profound deficiency in HSCs and/or multipotent progenitors (see Figure 16).
  • Bone marrow (BM) transplant of Erg-defective BM cells shows that the HSCs and hematopoietic progenitors are substantially defective in one or more of their functional activities such as, but not limited to, homing, engrafting, survival (i.e. not undergoing apoptosis) survival, self-renewal and differentiation (see Figure 17 and Brief Description of the Figures).
  • HSCs and hematopoietic progenitors are substantially defective in one or more of their functional activities such as, but not limited to, homing, engrafting, survival (i.e. not undergoing apoptosis) survival, self-renewal and differentiation (see Figure 17 and Brief Description of the Figures).
  • Erg-normal BM cells even on a background of no thrombopoietin facilitated normal hematopoiesis in myeloablated subjects (see Figure 18 and Brief Description of the Figures).
  • the present invention provides agents (modulators) that modulate the Erg signalling pathway.
  • the subject agents are useful for modulating the development and activity of multipotent progenitor cells including hematopoietic stem cells (HSC).
  • HSC hematopoietic stem cells
  • Hematopoietic stem cells are undifferentiated cells that give rise to a succession of mature functional blood cells as found in normal adults. This process is described as definitive hematopoiesis.
  • HSC reside in the bone marrow, peripheral blood, liver, spleen and other organs.
  • HSC are the first in a hierarchy of progenitor cells. They are capable of long-term self renewal (long term (LT)-HSCs).
  • LT-HSCs differentiate into short-term multipotent HSCs, (ST-HSCs) that retain the ability to produce all blood types but only proliferate for a relatively short time.
  • lymphoid progenitors arise that ultimately produce immune cells
  • myeloid progenitors arise that ultimately produce mainly red blood cells and platelets and some innate immune cells.
  • These progenitor cells have various abilities to proliferate and differentiate and from these cells ultimately arise terminally differentiated cells.
  • reference to HSC and hematopoietic progenitors include all the above mentioned progenitor cells and reference to hematopoietic or blood cells include any of their terminally differentiated descendants.
  • the agents are useful to treat or prevent aberrant hematopoiesis including aberrant haematopoietic cell activity.
  • the modulator enhances or down regulates the activity of Erg polypeptide, or a transcriptional target of Erg polypeptide or a down system effector of Erg polypeptide activity in a cell.
  • a transcriptional target is a gene to which Erg polypeptide binds or its expression product.
  • the transcriptional target is the regulatory region of a gene to which Erg polypeptide binds to modulate transcription.
  • upregulation of the activity of Erg in a subject using Erg polypeptide or a variant thereof or an agent from which an Erg polypeptide or variant thereof is producible or an agent that effectively enhances Erg activity are proposed to be useful for enhancing hematopoietic cell activity or for treating or preventing conditions associated with defective hematopoietic cell activity.
  • the hematopoietic cell is an erythrocyte, in other embodiments, a leukocyte.
  • the cell is a HSC or a hematopoietic progenitor cell.
  • agents that down regulate the functional activity of Erg in a cell are proposed for use in lowering platelet levels in a subject. Elevated platelet levels (thrombocytosis) may increase the risk of blot clots and is observed after surgery, in iron deficient anaemia and myeloproliferative diseases.
  • agents that down regulate the functional activity of Erg are proposed for use in treating or preventing clonal hemopathies including those that result from overactivity or dysregulated replication of stem cells such as found in cancer.
  • the subject agents bind to Erg i.e. all or part of coding, non-coding or regulatory regions in Erg DNA or RNA and modulate gene expression at transcriptional or post-transcriptional, including translational stages.
  • the agent binds to a transcriptional target of Erg and modulates its activity.
  • Genetic agents which reduce the activity of Erg polypeptides or a transcription target of Erg in a cell include genetic agents (i.e. comprising a nucleic acid molecule) which inhibit production of Erg in a cell at any stage including, for example, post-transcriptional silencing mediated by RNAi (see for example, United States Publication No. 20070042983, International Publication No. WO 01/68836 and International Publication No. WO 03/064626).
  • Such nucleic acids can be chemically synthesised, expressed from a vector or enzymatically synthesised as known in the art.
  • agents agents which effectively modulate, directly or indirectly, the activity of Erg polypeptide or one or more of its transcriptional targets in a cell.
  • modulators a broad range of modulators will be effective in modulating Erg activity or the activity of its transcriptional targets.
  • the present invention provides methods for screening and testing agents for their ability to modulate Erg activity including Erg signalling pathways and/or Erg- associated transcription.
  • Erg regulates the expression of genes encoding hematopoietic signalling molecules such as cytokine, chemokine, hormones or their cellular or nuclear receptors or transcription factors.
  • Erg regulates the expression of genes encoding signalling molecules or their receptors or transcription factors that are expressed in the early stages of hematopoietic stem cell development and differentiation.
  • Exemplary transcriptional targets include without limitation, Tpo, flt3L, SCF, MpI, scl, IL-6, IL-I l, TGF- ⁇ and the genetic region of the genes encoding those cytokines to which Erg polypeptide binds.
  • Modulation of HSC and/or hematopoietic progenitor cell activity may be effected in vitro or in vivo.
  • the present invention provides agents capable of modulating the activity of Erg polypeptide for use in the treatment of conditions associated with an over supply or an under supply of hematopoietic stem cells and/or progenitor cells.
  • the present invention provides a composition comprising Erg or an agent from which Erg is producible or a variant of either of these which enhances the activity of Erg polypeptide or Erg genetic sequences or Erg transcriptional targets.
  • such compositions or agents are for use in modulating hematopoiesis.
  • modulation is potentiation or upregulation.
  • the present invention also contemplates a composition comprising an agent which down regulates the activity of Erg in a cell or subject.
  • such compositions or agents are for use in modulating hematopoietic cell activity or for treating or preventing clonal hemopathies.
  • Efforts to reduce platelet numbers may be indicated to reduce the risk of a blood clot say after surgery, or in a subject with a myeloproliferative disorder, anaemia or cancer. Reduction in stem cell activity may be used to treat such conditions.
  • enhancement of the activity of Erg in a cell or subject permits the normal or enhanced production i.e., up-regulates the production of platelets from megakaryocytes.
  • enhancement of activity of Erg potentiates the development, survival, or proliferation (collectively referred to as "activity") of early hematopoietic cells such as HSC and their progeny. Elevated platelet numbers may be required in the treatment of autoimmune conditions (such as systemic lupus or autoimmune hemolytic anaemia), cancer and blood clotting disorders.
  • autoimmune conditions such as systemic lupus or autoimmune hemolytic anaemia
  • the ability to modulate stem cell levels in a subject or in vitro has a wide range of applications in conditions associated with an under supply or activity of stem cells or an over supply or activity of stem cells.
  • the present invention provides a method of modulating early hematopoietic cell activity in a mammalian subject comprising administering to the subject an effective amount of an agent that modulates the activity of Erg and/or its transcriptional targets in the subject.
  • the early hematopoietic cell is a HSC and/or a hematopoietic progenitor cell.
  • the cell is a mature blood cell including B and T lymphocytes, natural killer (NK) cells, granulocytes, monocytes, macrophages, erythrocytes and/or platelets.
  • the present invention provides a method of increasing the activity of hematopoietic cells, HSC or progenitor cells in vitro comprising contacting a cell with an effective amount of an agent that enhances the activity of Erg in the cell.
  • the hematopoietic cell is a HSC cell and/or a hematopoietic progenitor cell.
  • the present invention provides a preparation of hematopoietic cells in a medium comprising an agent that modulates Erg activity.
  • the hematopoietic cell is a HSC or a multipotent or committed hematopoietic progenitor cell.
  • agents and compositions of the present invention include small or large chemical molecules, peptides, polypeptides, proteins or nucleic acid molecules including antisense or other gene silencing molecules, and their precursors or derivatives.
  • agent or modulating include isolated cellular agents, cells (including genetically modified HSC or hematopoietic progenitor cells), plasmids or vectors comprising these agents.
  • the present invention further provides methods of screening or diagnosis to determine whether or not a subject has a hematological disorder such as a thrombocytopenia or a stem cell defect associated with a loss of function of Erg or is susceptible to developing same comprising screening a sample from the subject for a loss of function mutation in Erg.
  • Figure 1 is a photographic representation depicting the results of automated hematological analysis to determine platelet, white blood cell and red blood cell counts in ENU treated mice. This led to the identification of a mouse with a dominant multilineage deficiency phenotype, carrying a mutation designated as mld2. Each spot represents the peripheral blood cell counts of a single mouse. The results from the same mice are shown in each graph. Each mouse contains a unique set of mutations. Counts from the mouse carrying mld2 are shown in filled in grey circle.
  • Figure 2 is a photographic representation depicting the results of automated hematological analysis to determine cell counts in mice.
  • the mld2 mutation causes deficiencies in all lineages in MpI "7' mice.
  • mld2/+ MpI ' ' mice were mated to +/+ MpV 1" mice.
  • the offspring were expected to include both mld2/+ MpV 1' and +/+ MpV 1" .
  • mice were found to have significantly fewer mature blood cells for all the lineages examined. Each spot indicates the peripheral blood count of an individual mouse, the black bar indicates the mean for each genotype and the error bars indicate the standard deviation.
  • Figure 3 is a graphical representation depicting survivorship of mld2/+ MpV 1" mice.
  • FIG 4 is a photographic representation depicting the results of automated hematological analysis to determine platelet, white blood cell and red blood cell counts in mld2/+ Mpl 'A mice.
  • Mpl +/' mice which carry mld2 have moderate deficiencies in WBCs and platelets.
  • the mld2 genotype of Mpl +/" mice was determined by SSLP genotyping in the mld2 candidate interval. Mice were bled at seven weeks. Each spot represents the peripheral blood count from a single mouse.
  • the black bar shows the mean for each genotype, and the error bars show the standard error of the mean.
  • Figure 5 is a graphical representation of sequence data showing that the mld2 mutation is a T to C base substitution in Erg.
  • These DNA sequence trace files show both T and C peaks in the mld2/+ heterozygote, but only a T peak at the same location in the wild type (+/+).
  • the amino acid sequence of Erg encoded by this length of DNA is shown under the trace in single letter code.
  • the S/P refers to the serine and proline residues encoded by the wild type and mld2 Erg genes respectively in the genome of mld2 heterozygotes.
  • Figure 6 is a representation of information regarding the source of Erg sequence aligned in Figures 7 and 8.
  • Figure 7 is a representation of an alignment of amino acid sequences of Erg homologs taken from sources set out in Figure 6.
  • Figure 8 is a representation of an alignment of nucleic acid sequences of Erg homologs taken from sources set out in Figure 6.
  • Figure 9 is a graphical representation of data showing the identification of the mld2 mutation in a forward genetic screen on a sensitised MpV ' background.
  • MpI ' ' ' C57BL/6 mice were injected with ENU as described previously and bred with isogenic females (Carpinelli et al, Proc. Natl. Acad. Sci. U. S. A., 101:6553-6558, 2004). Blood was taken from their progeny at 7 weeks and analysed on an automated hematological analyser.
  • mice had low numbers of erythrocytes, leukocytes and platelets relative to MpI ' ' ' mice.
  • the mutation responsible for this multilineage defect was designated mld2.
  • Each circle represents the peripheral blood cell count of a single mouse, the results from the same mice are shown in each graph. The mouse carrying the mld2 mutation is shown in red.
  • Figure 10 is a graphical representation of data showing that mld2/+ mice are anaemic, leukopenic and thrombocytopenic.
  • the mld2/+ MpI ' ' ' founder mouse was mated to +/+ MpI " mice to further investigate the mld2 phenotype and its inheritance.
  • the progeny were bled at seven weeks.
  • the RBC counts of these progeny split into two clearly demarcated populations and genotypes were inferred on this basis (mld2/+ MpT 1" for RBC ⁇ 8.0 per pL (blue), +/+ Mpl 'f" for RBC > 8.0 per pL (green)).
  • mld2/+ MpI ' ' mice have an approximately 47% deficiency in RBCs.
  • mld2/+ MpI ' ' ' also appear to have deficiencies in all lineages of leukocytes (54% deficient overall) as well as platelets (80% deficient, Figure 2).
  • mutated gene see below
  • Each circle represents the peripheral blood cell count of a single mouse, the results from the same mice are shown in each graph. The means and standard deviations mice of each inferred genotype are also shown.
  • Figure 11 is a diagrammatical representation of data showing that the mld2 mutation maps to a 1.6 megabase interval on chromosome 16.
  • a positional cloning strategy was used to identify the region of the genome carrying the mld2 mutation. Briefly, mld2/+ MpI ' ' ' C57BL/6 mice were crossed to wild type Balb/c mice. The G 1 progeny were then crossed to +/+ MpI ' ' " C57BL/6 mice.
  • the genotypes of short sequence length polymorphic (SSLP) genetic markers nearest to the mld2 mutation will be homozygous C57BL/6 in all mice carrying mld2, and conversely they will be heterozygous in those not carrying it.
  • the mld2 mutation can be localised by finding the smallest region of markers for which this remains true (indicated by a red box).
  • G 2 MpI ' ' ' mice could easily be shown to be affected by the mld2 phenotype by the presence of the characteristic multilineage defect, and the capacity to pass this defect to their progeny.
  • the mld2 mutation was localised to a 1.6 megabase (Mb) interval on the distal end of chromosome 16. This interval contains 8 genes.
  • the data represents the haplotypes of mice used to define the mld2 candidate interval.
  • the number of mice affected and unaffected by the mld2 mutation with each haplotype is shown. Markers used and their positions on the April 2006 University of California, Santa Cruz (UCSC) mouse genome are indicated.
  • C homozygous C57BL/6 genotype
  • H heterozygous C57BL/6 and Balb/c genotype
  • Mb megabases.
  • Figure 12 is a graphical representation of data showing that the mld2 mutation is predicted to cause a serine to proline substitution in the DNA binding domain of the ETS transcription factor Erg.
  • the 1.6 megabase mld2 candidate interval contained 8 genes. One of these genes encodes the ETS transcription factor Erg.
  • ETS transcription factors have been implicated in hematopoiesis, so the coding exons and intron-exon boundaries of Erg were sequenced.
  • a T to C nucleotide substitution was identified in exon 12 of Erg in all mld2/+ mice, but in no +/+ mice. This is predicted to cause a serine to proline substitution in the ETS domain of Erg.
  • This mutation lies immediately distal to an alpha helix highly conserved amongst the 26 ETS family genes in the mouse and so may be predicted to disrupt one or more functions of this DNA binding domain.
  • the data shown represents: (A) Electropherograms showing the nucleotide sequence of exon 12 of Erg from a +/+ and mld2/+ mouse, along with the predicted amino acid sequence of Erg. (B) The predicted amino acid sequences of the ETS domain of Erg in different species. The residue affected by the mld2 mutation is highlighted in yellow.
  • Figure 13 is a diagrammatical representation of data showing that Erg mld2/+ mice are leukopenic and thrombocytopenic on a Mpl +/+ genetic background.
  • Erg'" ld2/+ MpV 1' C57BL/6 mice were successively mated with Erg +/+ Mpl +/+ C57BL/6 in order to generate Erg mld2/+ Mpl +/+ mice.
  • At 7 weeks of age blood from these mice and Erg +/+ Mpl +/+ littermates was analysed.
  • Erg'" ld2/+ Mpt /+ mice showed no deficiency in erythrocytes, exhibited an approximately 40% reduction in leukocytes and platelets.
  • the data shown represents the means ⁇ standard deviations of the blood cell counts from five mice of each genotype. The data in each of the three graphs is from the same five mice.
  • Figure 14 is a graphical representation of data showing Erg" 1 2 + MpT mice exhibit decreased survival.
  • Erg'" ld2/+ MpT 1' mice demonstrated reduced survival, while Erg +/+ MpT 1' , Erg mld2/+ Mpl +/' and Erg +/+ Mpl +/' mice exhibited no decrease in survival. Therefore, mice with one mutant Erg allele only show decreased survival in the absence of functional MpI. Approximately 200 ⁇ L of blood was taken from all these mice at three weeks. Preliminary data from post mortem analyses suggests that this illness is associated with internal haemorrhaging under the skin, around the joints and in the skull.
  • the data shown is a Kaplan-Meyer plot where a mouse being found dead, or discarded due to illness is represented by a drop in the curve, whereas the discarding of healthy mice from the colony due their being excess to our requirements is represented by vertical tick marks on the curve.
  • Figure 15 is a diagrammatical representation of data showing that Erg mld2/+ Mpl +/+ mice exhibit deficiencies in a range of lineage committed hemopoietic progenitors.
  • the frequency of blast, neutrophil (G), neutrophil-macrophage (GM), macrophage (M), eosinophil (Eo) and megakaryocyte (Meg) colony forming cells (CFC) in bone marrow (BM) was determined by the clonal culture of hematopoietic precursors with the stimulation of stem cell factor, interleukin-3 and erythropoietin, as described previously (Alexander et al, Blood, 87:2162-2170, 1996).
  • mice had an approximately 50% deficiency in lineage-committed progenitor cells from all of these hematopoietic lineages.
  • the data shown represents the means and standard deviations of the frequency of CFCs in five mice of each genotype.
  • Figure 16 is a diagrammatical representation of data showing that Erg'" ld2/+ mice exhibit a severe deficiency in multipotent progenitor activity.
  • CFU-s spleen colony forming units
  • mice Eight days later, the spleens were dissected from the recipients and macroscopic spleen colonies counted after fixation in Carnoy's fixative.
  • Erg mld2/+ MpV 1' mice exhibited a profound reduction in the multipotent, early hematopoietic progenitors that form spleen colonies in comparison to Erg + MpV ' mice.
  • Erg mld2/+ Mpl +/+ mice were approximately 50% deficient in CFU-s in comparison to Erg +/+ Mpl +/+ mice. This provides compelling evidence of a profound, bone marrow intrinsic deficiency in HSCs and/or multipotent progenitors in mice with one mutant Erg allele.
  • the data shown represents the means and standard deviations of the frequency of CFU-s in bone marrow from three Erg mld2/+ MpI ' ' mice, three Erg +/+ MpV 1' mice, five Erg m!d2/+ Mpl +/+ mice and five Erg mld2/+ Mpl +/+ mice.
  • Figure 17 is a diagrammatical representation of data showing that Erg m!d2/+ bone marrow shows defects in the reconstitution of hematopoiesis after transplantation into myeloablated recipient mice.
  • mice reconstituted with Erg mld2/+ Mpl +/+ BM show leukopenia and thrombocytopenia indistinguishable to that observed in the peripheral blood of Erg mld2/+ Mpl +/+ mice.
  • Erg mld2/+ Mpl +/+ BM is defective in its ability to reconstitute all blood cell lineages relative to wild type cells, it is able to contribute to all these cell lineages.
  • Erg mId2/+ MpU 1+ BM can home, engraft, survive, self-renew and differentiate but that, relative to wild type cells, one or more of these functions is compromised by the mutation of Erg.
  • Erg m 2 + MpI + + mice can survive normally with blood cells of all lineages, while remaining an excellent model in which HSC deficiencies and regulation may be investigated.
  • BM was transplanted from two Erg mld2/+ Mpl +/+ mice and two Erg +/+ Mpt /+ mice.
  • the data shown represent: (A) The means and standard deviations of the average proportion of blood cells derived from donor BM after reconstitution. The contributions to multiple blood cell lineages are shown. (B) The means and standard deviations of the average peripheral blood cell counts observed in the recipitents of BM. This data is from the same mice as shown in (A).
  • Figure 18 is a diagrammatical representation of data showing that Erg mld2/+ bone marrow cannot compete with wild type bone marrow during the reconstitution of hematopoiesis.
  • competitive transplants were performed. 1 x 10 6 Erg mld2/+ MpI+ or Erg +/+ MpV 1' Ly5.1 " Ly5.2 + test bone marrow (BM) cells were injected along with 1 x 10 6 Erg +/+ MpI ' ' ' Ly5.1 + Ly5.2 " competitor BM cells into C57BL/6 Ly5.1 + Ly5.2 " recipients which had been myeloablated by irradiation.
  • Figure 19 is a photographical representation of data showing that the mld2 missense mutation does not effect the DNA binding of Erg.
  • electrophoretic mobility shift assays were performed (EMSA). FLAG epitope-tagged Erg and Erg mld2 were affinity purified from the lysates of 293T human embryonic kidney cells transfected with a mammalian expression vector to overexpress these proteins.
  • Amounts of the resulting enriched Erg and Erg mld2 solutions containing equivalent amounts of each protein were mixed with IOng of radiolabeled E74 probe, a double stranded oligonucleotide which contains a sequence that is specifically bound by ETS transcription factors, in DNA binding buffer (13mM Tris pH 7.5, 2.6mM MgCl 2 , 1.3mM dithiothreitol, 260 ⁇ M spermadine, 260 ⁇ M EDTA) with water, 200ng unlabelled E74, 200ng unlabelled E74 mut (in which has two nucleotides have been altered to ablate the ETS binding site), 2mg biotinylated M2 anti-FLAG antibody, or 2mg biotinylated mouse IgG 1 . After 15 minutes incubation, probe/protein complexes were resolved from unbound probe by electrophorhesis through a 10% acrylamide-TBE gel.
  • Probe/protein complexes were detectable when either Erg or Erg mld2 solutions were mixed with labelled E74 indicating that protein in both the solutions could bind this oligonucleotide.
  • the data shown represents: (A) The sequence of the E74 and E74 mut oligonucleotides. The ETS binding site is shown in bold, the two nucleotides altered to remove the ETS binding site are highlighted yellow. (B) An autoradiograph of an EMSA gel. Each lane was loaded with E74 radiolabeled probe. Lane 2 was also loaded with affinity purified cell lysate from cells transfected with an empty mammalian expression vector (mock). Lanes 3, 5, 7, 9 and 11 were loaded with affinity purified cell lysate from cells transfected with a mammalian expression vector transfected to overexpress wild type (WT) Erg.
  • WT wild type
  • Lanes 4, 6, 8, 10 and 12 were loaded with affinity purified cell lysate from cells transfected with a mammalian expression vector transfected to overexpress Erg mld2 .
  • Lanes 5 and 6 were loaded with unlabelled E74.
  • Lanes 7 and 8 were loaded with unlabelled E74 mut .
  • Lanes 9 and 10 were also loaded with M2 anti-FLAG antibody.
  • Lanes 11 and 12 were also loaded with mouse IgG 1 . Underneath the autoradiograph, a silver stained SDS-PAGE gel shows the protein content of the enriched cell lysates loaded into each lane.
  • Figure 20 is a photographical representation of data showing that the mld.2 mutation disrupts the ability of Erg to transactivate transcription.
  • COS monkey kidney cells were transfected with a firefly luciferase gene under the transcriptional control of a herpes simplex virus thymidine kinase promoter, which contains several canonical ETS transcription factor binding sites.
  • Cells were cotransfected with one or more of the following - pEF-BOS, a mammalian expression vector; pEF-FLAG-Erg, the same vector, but with a cDNA insert encoding FLAG epitope- tagged Erg, so that Erg is overexpressed; or pEF-FLAG-Erg mld2 3 which results in the overexpression of FLAG epitope-tagged Erg mld2 . Luciferase activity was measured using a commercial luciferase assay kit (Promega).
  • the data shown represent the means ⁇ standard deviations of the luciferase activity of five wells of cells transfected with the plasmids shown.
  • a Western blot probed with antibodies against the FLAG-epitope and Hsp70 (a housekeeping gene) is also shown.
  • the bands representing Erg and Hsp70 on the blot are shown, as is the size of protein standards (in kDa).
  • Figure 21 is a graphical representation of data showing that the mld2 mutation disrupts the biological activity of Erg.
  • the effect of the mld2 mutation on the biological activity of Erg was investigated by studying its expression in K562 eythroleukemia cells.
  • the overexpression of Erg in K562 erythroleukemia cells has been shown to induce the megakaryocyte antigens CD41 and CD61 (Rainis et al., 2005 ⁇ supra)).
  • K562 cells with one of three vectors: pEF-Erg-IRES-GFP, a bicistronic plasmid that encodes Erg and green fluorescent protein (GFP); pEF-Erg mld2 -IRES-GFP, which encode Erg mld2 and GFP; or pEF-IRES-GFP, which encodes GFP alone.
  • pEF-Erg mld2 -IRES-GFP which encode Erg mld2 and GFP
  • pEF-IRES-GFP which encodes GFP alone.
  • Table 1 provides a description of the SEQ ID NOs provided herein.
  • Table 2 provides an amino acid sub-classification.
  • Table 3 provides exemplary amino acid substitutions.
  • Table 4 provides a list of non-natural amino acids contemplated in the present invention.
  • Table 5 presents data demonstrating that the mld2/+ MpT 1' genotype causes severe deficiency in HSC and/or multipotential progenitor activity.
  • Cells derived from mld2/+ MpV 1' marrow make a negligible contribution to hematopoiesis when in competition with +/+ Mpf ' marrow.
  • the mean percentage contribution ⁇ standard deviation is shown.
  • 1 x 10 6 Ly5.1 ' Ly5.2 + test cells were transplanted with 1 x 10 6 Ly5.1 + Ly5.2 " +/+ MpT 1' competitor cells into five Ly5.1 + Ly5.2 + irradiated recipients. Data shown are percentages of total circulating nucleated cells.
  • Table 6 presents data indicating survivorship in progeny of heterozygous mld2/+ Mpf ' mice. Mice with the mld2/mld2 homozygous genotype do not survive until birth. The table shows a number of progeny of a mld2/+ MpI + " intercross, genotyped at weaning by SSLP markers surrounding the known location of the mld2 mutation.
  • Table 7 provides survivorship data for progeny of mice generated carrying the Mld2 mutation showing that the Mld2 mutation is lethal in homozygous form. While generating mice carrying the mld2 mutation, we observed that no Erg m!d2/m!d2 pups were present at weaning. To investigate this apparent lethality, we examined the embryonic progeny of
  • Tables 8 and 9 provides data showing that mutations in Erg reduce the cellularity and number of colony forming cells in yolk sacs and fetal livers dissected from embryos at 10.5 days post conception.
  • embryonic hematopoiesis was analysed.
  • One of the earliest sites of blood cell production in the embryo is the yolk sac, the membranous tissue surrounding the developing fetus. Later in embryogenesis hematopoiesis shifts to the fetal liver and then ultimately to the bone marrow and spleen.
  • Counts of embryonic hematopoietic progenitor cells were determined by an in vitro clonal assay of yolk sac cell suspensions and fetal liver cells from embryonic day 10.5 and 12.5 fetuses respectively, using cytokines to stimulate colony formation using previously described methods (Alexander et ah, 1996 (supra)). These analyses revealed that the overall cellularity of the fetal liver and yolk sac was considerably reduced and numbers of progenitor cells of all measured hematopoietic lineages were deficient in homozygous mld2/mld2 mice, when compared with mld2/+ or wild type mice. A trend towards reduced cellularity and deficient hematopoietic progenitor cell numbers was also observed in mld2/+ tissues compared with wild type.
  • the data shown is the means ⁇ standard deviations of the numbers of hematopoietic colony-forming cells in yolk sac and fetal liver suspensions cultured in stem cell factor + interleukin-3 + erythropoietin for 7 days at 37 0 C in 5% CO 2 in air.
  • G granulocyte; GM, granulocyte-macrophage; M, macrophage; Eo, eosinophil; Meg, megakaryocyte; Ery, erythroid; Myel, myeloid (granulocyte, macrophage).
  • the invention is predicated, in part, upon the determination that Erg polypeptide function is important for megakaryocytopoiesis (platelet production) and leukocytopoiesis and also for the proper or uncompromised activity of early hematopoietic cells such as hematopoietic stem cells and/or progenitor cells.
  • An Erg polypeptide as defined herein may be used in the expansion of hematopoietic stem cells and/or multipotent or committed hematopoietic progenitor cells of various blood lineages, and in the differentiation and/or proliferation of various hematopoietic cell types.
  • Erg, Erg and variants of these or agents that modulate Erg activity in a subject may also be used to treat or prevent various disorders or conditions associated with stem cell, progenitor cell or various different blood cell defects.
  • stem cells to self-renew are shared by neoplastic cells which can aberrantly replicate until they overwhelm the body.
  • the regulatory mechanisms of cancer cell and stem cell proliferation may therefore have overlapping characteristics.
  • a fully differentiated cell may take on the self-renewing phenotype of stem cells.
  • stem cells may assume a dysregulated self-renewal phenotype to form cancerous cells.
  • Reference herein to a hematological disorder or condition or similar grammatical expressions include, without limitation, thrombocytopenias, thrombocytosis, anaemias including drug induced anaemia, leukopenia, immunological disorders, autoimmune disorders, myeloproliferative disorders, cancer, conditions associated with stem cell defects or dysregulated proliferation or differentiation and bone marrow defects.
  • Examples of particular conditions include without limitation: leukemia, Hodgkin's disease, non- Hogkin's lymphoma, acute lymphocytic anaemia, plasmacytomas, multiple myeloma Burkett's lymphoma, arthritis, asthma, AIDS, rheumatoid arthritis, granulomatous disease, immune deficiency, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, immune reaction to transplanted organ, SLE, hemophilia, hypercoagulation, diabetes, meningitis, lyme disease and allergies.
  • Autosomal recessive traits include: Fanconi Syndrome, Thrombocytopenia with absent radius (TAR) syndrome, Bernard-Soulier syndrome, Gray platelet syndrome, and Isolated thrombocytopenia.
  • Autosomal dominant traits include: May-Hegglin anomaly, Alport syndrome variants, and Isolated thrombocytopenia.
  • X-linked traits include: Wiskott- Adrich syndrome, and Isolated thrombocytopenia.
  • hematopoietic disorders are selected from the group consisting of: aplastic pancytopenias (traditionally known as aplastic anaemia), which result from aplasia or suppression of hematopoietic stem cells, including: Fanconi's anaemia, Shwachman- Diamond syndrome, Dyskeratosis congenita, Amegakaryocytic thrombocytopenia.
  • aplastic pancytopenias traditionally known as aplastic anaemia
  • Fanconi's anaemia Shwachman- Diamond syndrome
  • Dyskeratosis congenita Amegakaryocytic thrombocytopenia.
  • Other genetic syndromes include Down's syndrome, Dubowitz's syndrome, Seckel's syndrome, Reticular dysgenesis, and Familial aplastic anaemia (non-Fanconi's).
  • the inhibition of Erg or its transcriptional targets or downstream effectors may be therapeutically useful in responding to the clonal hemopathies that result from the overactivity or replication of stem cells.
  • These include: Preleukaemias (myelodysplasias) such as Idiopathic refractory sideroblastic anaemia, Idiopathic refractory nonosideroblastic anaemia, Pancytopenia with hyperplastic marrow, Monoclonal aplastic anaemia, and Paroxysmal nocturnal hemoglobinuria.
  • myeloproliferative diseases such as Chronic myeloproliferative diseases including Polycythemia vera, Chronic myelogenous leukemia (CML), Primary thrombocythemia, Idiopathic myelofibrosis, Subacute myeloproliferative disorders, Oligoblastic (smoldering) leukemias, Refractory leukemias with excess myeloblasts, Myelomnocytic leukemia, and Atypical myeloproliferative syndromes.
  • Chronic myeloproliferative diseases including Polycythemia vera, Chronic myelogenous leukemia (CML), Primary thrombocythemia, Idiopathic myelofibrosis, Subacute myeloproliferative disorders, Oligoblastic (smoldering) leukemias, Refractory leukemias with excess myeloblasts, Myelomnocytic leukemia, and Atypical myeloproliferative syndromes.
  • acute myeloproliferative disorders such as Acute myelogenous leukemia, Myeloblasts (granuloblasts), Promyelocytic: associated with intravascular coagulation, Myelomonocytic(granlomonoblastic), Monocytic: associated with tissue infiltration, Erythroid, Megakaryocyte: associated with marrow fibrosis, Eosinophilic: associated with heart and lung fibrosis and Basophilic and Mast Cell.
  • acute biphenotypic myeloid and lymphoid markers
  • the present invention provides a method of modulating hematopoietic cell activity wherein the hematopoietic cell is selected from the group consisting B or T lymphocytes, natural killer (NK) cells, granulocytes, monocytes, macrophages, erythrocytes and platelets.
  • the method is conducted in vitro or in vivo.
  • an agent that modulates the activity of Erg in a cell is administered to a subject in need thereof.
  • the cell is contacted in vitro with an effective amount of the agent sufficient to enhance the activity of Erg therein.
  • the present invention extends to animal and cellular models comprising Erg having a modified (including no) Erg activity such that the effects of modified Erg activity on blood cell development and function can be determined. Such models are also useful to screen for and test agents that have potential as therapeutic agents when these functions are impaired.
  • the present invention provides an isolated cell, or a non-human animal comprising such cells, wherein Erg or Erg is modified to effectively modulate the functional effect of Erg in the cell or animal compared to a non-modified animal of the same species.
  • Cells may be derived from human or non-human animal sources.
  • the term "derived” does not necessarily mean that the cells are directly obtained from a particular source.
  • Reference to a "cell” includes a system of cells such as a particular tissue or organ.
  • modified includes genetically modified but encompasses non-genetic or epigenetic modifications to affect Erg activity by, for example, the administration of an agent such as, without limitation, an organic or inorganic chemical agents, antibody, enzyme, peptide, genetic or proteinaceous molecule to effectively modulate the functional activity of Erg.
  • an agent such as, without limitation, an organic or inorganic chemical agents, antibody, enzyme, peptide, genetic or proteinaceous molecule to effectively modulate the functional activity of Erg.
  • Reference herein to "modulate” and “modulation” includes completely or partially inhibiting or reducing or down regulating all or part of Erg functional activity and enhancing or up regulating all or part its functional activity.
  • Functional activity may be modulated by, for example, modulating Erg nucleic acid binding capabilities or transcriptional or translational activity, or its half-life.
  • Erg polypeptide its functional activity may be modulated by, for example, modulating its binding capabilities, its half-life, location in a cell.
  • Erg level or activity may be modulated by modulating
  • Reference to the "activity" or “functional activity” of Erg encompasses any relevant, measurable activity or characteristic of the molecule in proteinaceous or genetic form and includes Erg polypeptide's specific DNA and protein binding abilities. Binding or transcriptional, translational or transactivational activity are preferred activities which are conveniently assessed using standard protocols known in the art as described in Sambrook, Molecular Cloning: A Laboratory Manual, 3 rd Edition, CSHLP, CSH, NY, 2001; Ausubel (Ed) Current Protocols in Molecular Biology, 5 th Edition, John Wiley & Sons, Inc, NY, 2002. For example, the ability of Erg to drive transcription is tested using luminescence reporter assays as shown in Figure 20.
  • the ability of Erg to modulate cellular activities such as proliferation, development or survival can be assessed visually, spectroscopically, or using instrumentation to evaluate the activity or a molecular marker or reporter of the activity. Other activities assayed include HSC homing, engrafting, apoptosis and self- renewal. Functional activity, in some embodiments is assessed by analysing cells comprising Erg (such as K562, see Rainis et ah, 2005 ⁇ supra)) for expression of megakaryocyte or leukocytic markers antigens for example, by flow cytometry (see Figure 21). The ability of Erg to bind DNA via its C-terminal ETS DNA binding domain is tested as described in the Brief Description of the Figures for Figure 19.
  • Erg such as K562, see Rainis et ah, 2005 ⁇ supra
  • Erg polypeptide The ability of Erg polypeptide to bind to proteins via the N-terminal pointer domain is also tested.
  • the Mld2 mutation (A, T and C nucleotide substitutions shown in Figure 12) does not affect the direct DNA binding function of Erg although its functional activity is disrupted (see Figure 21 and Brief Description of the Figures).
  • Erg polypeptide stimulates a characteristic gene expression profile which serves as a useful marker of Erg activity.
  • the gene expression profile of a cell when Erg polypeptide activity is down- regulated or inhibited serves as a useful marker of lack of Erg activity.
  • Such assays may be conveniently adapted for high throughput evaluation, for example, cytometrically such as by flow cytometry, array technology such as microarray technology, antibody technology, chromatographic methods such as HPLC or thin layer chromatography or combinations of these. Binding is conveniently detected using antibodies.
  • In vitro or in v/vo assays can employ a wide range of markers or indicators of Erg activity using, for example, the methods exemplified herein. For example, platelet levels or turnover may be measured using automated hematological analysis; transcriptional activity may, for example, be assessed by measuring the level of specific RNA produced or may be assessed via measuring the activity of a reporter molecule.
  • references herein to the "activity” or “overactivity” and the like, in relation to cells include without limitation a reference to any one or more of the following: cellular development, proliferation, cellular differentiation, cell function such as homing, engraftment, self- renewal, survival differentiation, cell number and cell survival.
  • cellular development, proliferation, cellular differentiation, cell function such as homing, engraftment, self- renewal, survival differentiation, cell number and cell survival.
  • self renewal phenotype of stem cells is tightly regulated. As stem cells divide their daughter cells maintain a critical balance between two fates: either retaining stem cell function, or alternatively differentiating into mature effector cells.
  • extension symmetric division where both daughter cells retain stem cell function and which results into expansion of stem cell population
  • maintenance asymmetric division which maintains the stem cell population by producing one daughter stem cell and one daughter cell committed to differentiation
  • committed symmetric division where both daughter cells are committed to differentiate.
  • activity includes reference to extension symmetric division, maintenance asymmetric divisional and/or committed symmetric division.
  • the activity of Erg may be monitored using DNA or protein binding assays, reporter assays or direct or indirect assays of Erg activity including the use of antibodies or other proteinaceous or genetic agents in a number of assays which are well known to those of skill in the art.
  • Antibodies may be used to detect Erg by Western Blotting, cytometric histochemical or ELISA procedures. As discussed herein below, such agents may also distinguish between active and inactive forms of the Erg or between mutant and normal forms of Erg.
  • mutant forms of Erg are forms of Erg (found in a population of subjects) which are associated with aberrant hematopoiesis, such as thrombocytopenia, clonal hemopathies, anaemia, leukemia etc. Normal forms are forms of Erg which are not associated with these conditions. Mutant forms of Erg may also be conveniently be detected using nucleic acid based assays well know in the art and as described herein.
  • Erg activity may be monitored indirectly by monitoring RNA production and/or stability or the levels of regulatory molecules such as enhancers and repressors.
  • Regulatory regions include promoters, polyadenylation signals, transcriptional enhancers, translational enhancers, leader or trailing sequences that modulate mRNA stability and targeting sequences that direct a product encoded by a transcribed nucleic acid molecule to a particular location such as an intracellular compartment or to the extracellular environment.
  • genetically modified refers to changes at the genome level and refers herein to a cell or animal that contains within its genome a specific gene which has been altered.
  • Alternations may be single base changes such as a point mutation or may comprise deletion of the entire gene such as by homologous recombination. Genetic modifications include alterations to' regulatory regions, insertions of further copies of endogenous or heterologous genes, insertions or substitutions with heterologous genes or genetic regions etc. Alterations include, therefore, single of multiple nucleic acid insertions, deletions, substitutions or combinations thereof. Cells and animals which carry a mutant Erg allele or where one or both alleles are deleted can be used as model systems to study the effects of Erg in hematopoietic cell development and function and/or to test for substances which have potential as therapeutic or teratogenic agents when these function are impaired.
  • Animals for testing therapeutic agents can be selected after mutagenesis of whole animals or after treatment of germline cells or zygotes. Such treatments include insertion of mutant Erg alleles (including those carrying loxP flanking sequences), usually from a second animal of the same species, as well as insertion of disrupted homologous genes. Alternatively, the endogenous Erg gene of the animals may be disrupted by insertion or deletion mutation or other genetic alterations using conventional techniques. These animal models provide an extremely important testing vehicle for potential therapeutic products.
  • the cells may be isolated from individuals with Erg mutations, either somatic or germline. Alternatively, the cell line can be engineered to carry the mutation in the Erg allele, as described above. After a test substance is applied to the cells, the phenotype of the cell is determined. Any trait of the cells can be assessed.
  • a genetically modified animal or cell includes animals or cells from a transgenic animal, a "knock in” or knock out” animal, conditional variants or other mutants or cells or animals susceptible to co-suppression, gene silencing or induction of RNAi.
  • targeting constructs are initially used to generate the modified genetic sequences in the cell or organism.
  • Targeting constructs generally but not exclusively modify a target sequence by homologous recombination.
  • a modified genetic sequence may be introduced using artificial chromosomes.
  • Targeting or other constructs including reporter constructs for screening potential Erg modulators are produced and introduced into target cells using methods well known in the art which are described in molecular biology laboratory manuals such as, for example, in Sambrook, 2001 (supra); Ausubel, 2002 (supra).
  • Targeting constructs may be introduced into cells by any method such as electroporation, viral mediated transfer or microinjection. Selection markers are generally employed to initially identify cells which have successfully incorporated the targeting construct. Genetically modified organisms are generated using techniques well known in the art such as described in Hogan et al, Manipulating the Mouse Embryo: A Laboratory Manual,
  • Stem cells including embryonic stem cells are introduced into the embryo of a recipient organism at the blastocyst stage of development.
  • ES cells are conveniently obtained from pre-implantation embryos maintained in vitro (Robertson et al., Nature 522:445-448,
  • modified cells are injected into the blastocyst or morula or other suitable developmental stage, to generate a chimeric organism.
  • modified cells are allowed to aggregate with dissociated embryonic cells to form aggregation chimera.
  • the chimeric organism is then implanted into a suitable female foster organism and the embryo allowed to develop to term.
  • Chimeric progeny are bred to obtain offspring in which the genome of each cell contains the nucleotide sequences conferred by the targeting construct.
  • Genetically modified organism may comprise a heterozygous modification or alternatively both alleles may be affected.
  • Another aspect of the present invention provides cells or animal comprising one, two or more genes or regions which are modified.
  • the genetically modified cells or animals may comprise a gene capable of functioning as a marker for detection of modified cells.
  • the instant animals may be bred with other transgenic or mutant non- human animals to provide progeny some of which exhibit one or both traits or a modified trait/s. Chimeric animals are also contemplated.
  • polynucleotide include RNA, cDNA, genomic DNA, synthetic forms and mixed polymers, both sense and antisense strands, and may be chemically or biochemically modified or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those skilled in the art. Such modifications include, for example, labels, methylation, substitution of one or more of the naturally occurring nucleotides with an analog (such as the morpholine ring), internucleotide modifications such as uncharged linkages (e.g. methyl phosphonates, phosphotriesters, phosphoamidates, carbamates, etc.), charged linkages (e.g.
  • phosphorothioates phosphorodithioates, etc.
  • pendent moieties e.g. polypeptides
  • intercalators e.g. acridine, psoralen, etc.
  • chelators e.g. acridine, psoralen, etc.
  • alkylators e.g. ⁇ -anomeric nucleic acids, etc.
  • synthetic molecules that mimic polynucleotides in their ability to bind to a designated sequence via hydrogen binding and other chemical interactions. Such molecules are known in the art and include, for example, those in which peptide linkages substitute for phosphate linkages in the backbone of the molecule.
  • the present invention further contemplates recombinant nucleic acids including a recombinant construct comprising all or part of Erg.
  • the recombinant construct may be capable of replicating autonomously in a host cell. Alternatively, the recombinant construct may become integrated into the chromosonal DNA of the host cell.
  • Such a recombinant polynucleotide comprises a polynucleotide of genomic, cDNA, semi-synthetic or synthetic origin which, by virtue of its origin or manipulation: (i) is not associated with all or a portion of a polynucleotide with which it is associated in nature; (ii) is linked to a polynucleotide other than that to which it is linked in nature; or (iii) does not occur in nature.
  • nucleic acids according to the invention include RNA, reference to the sequence shown should be construed as reference to the RNA equivalent with U substituted for T.
  • Such constructs are useful to elevate Erg levels or to down-regulate Erg levels such as via antisense means or RNAi-mediated gene silencing. As will be well known to those of skill in the art, such constructs are also useful in generating animal models carrying modified alleles of Erg and, as .pharmaceutical compositions for modulating the activity of Erg in a subject in vivo.
  • Genetically modified cells or non-human organisms may be provided in the form of cells or embryos for transplantation. Cells and embryos are preferably maintained in a frozen state and may optionally be distributed or sold with instructions for use.
  • the present invention provides a genetically modified cell, or non- human animal comprising such cells, wherein a Erg gene is modified and the cell or animal produces a substantially enhanced level or activity of Erg polypeptide, or substantially reduced level or activity of Erg polypeptide compared to a non-modified animal of the same species, or is substantially incapable of producing Erg polypeptides.
  • the genetically modified cells and non-human animals may be a non-human primate, livestock animal, companion animal, laboratory test animal, captive wild animal, reptile, amphibian, fish, bird or other organism.
  • the genetically modified non-human animal is a murine animal.
  • the modified cell or non-human animal is genetically modified and produces a substantially reduced level of Erg or is substantially incapable of producing Erg or produces Erg having substantially reduced or no activity.
  • an Erg gene is modified. Modification may be in one or both alleles and may optionally be within a regulatory region of the gene.
  • the genetic modification resulting in a cell or animal capable of exhibiting a modified level or activity of Erg comprises genetic modification outside the Erg gene to cause expression of genetic or proteinaceous molecules which effectively modulate the activity of Erg or Erg.
  • the modified cell or non-human animal is genetically modified and substantially overproduces Erg having normal or altered activity relative to an unmodified cell or animal of the same species.
  • the invention provides a method of screening for or testing an agent capable of complementing a phenotype shown by a cell or non-human animal comprising a modified Erg nucleic acid or Erg polypeptide and exhibiting a substantially modified level or activity of Erg polypeptide.
  • the cell or animal is contacted with the agent and its effect on the activity of Erg or its transcriptional targets determined.
  • the method comprises screening for mutants which exhibit a complementing phenotype and then mapping and identifying the modifying gene.
  • the method comprises screening for agents which enhance the level or activity of Erg in a normal or modified cell.
  • small-molecule libraries are screened for agents which directly or indirectly modulate Erg polypeptide activity.
  • the subject invention provides a use of a cell or non-human animal comprising a modified Erg or Erg and exhibiting a substantially reduced level or activity of Erg in screening for or testing agents for use in the treatment or prophylaxis of a hematological disorders as described further herein.
  • a substantially reduced level or activity of Erg is conveniently assessed in terms of a percent reduction relative to normal cells or animals or pre-treatment/pre-administration.
  • a substantial reduction includes one which results in detectable thrombocytopenia in a subject or aberrant haematopoietic cell activity.
  • a reduced level of gene expression of transcription targets or a reporter thereof is detected.
  • the reduction is at least 20% compared to normal cells, more preferably about 25%, still more preferably at least about 30% reduction, more preferably at least about 40% reduction in
  • Erg level or activity The reduction may of course be complete loss of Erg activity in a cell or animal.
  • a "modified" level or activity includes enhanced levels of Erg activity relative to pre-treatment levels and may equate to or exceed the level or activity of Erg detectable in healthy subjects, control cells or cell-free systems or in subjects unlikely to develop thrombocytopenia, stem cell or bone marrow defects.
  • the present invention further provides a method for identifying agents useful in the treatment or prophylaxis of hematological disorders such as described herein comprising screening compounds for their ability to modulate the functional activity of Erg polypeptides.
  • the present invention provides a composition comprising an agent which up regulates the level or activity of Erg in a cell for use in modulating hematopoietic cell levels including stem cells, early progenitor cells and platelet cells in vivo or in vitro.
  • down regulation or Erg activity will be useful in the treatment or prevention of clonal hemopathies including those hereinbefore described.
  • the modulatory agents of the present invention may be chemical agents such small or large organic or inorganic chemical molecules, peptides, polypeptides including dominant negative forms, modified peptides such as constrained peptides, foldamers, peptidomimetics, cyclic peptidomimetics, proteins, lipids, carbohydrates or nucleic acid molecules including antisense or other gene silencing molecules.
  • Small molecules generally have a molecular mass of less than 500 Daltons.
  • Large molecules generally include whole polypeptides or other compounds having a molecular mass greater than 500 Daltons.
  • Agents may comprise naturally occurring molecules, variants (including analogs) thereof as defined herein or non-naturally occurring molecules.
  • Gene silencing agents such as DNA (gDNA, cDNA), RNA (sense RNAs, antisense RNAs, niRNAs, tRNAs, rRNAs, small interfering RNAs (SiRNAs), short hairpin RNAs (ShRNAs), micro RNAs (miRNAs), small nucleolar RNAs (SnoRNAs, small nuclear (SnRNAs)) ribozymes, aptamers, DNAzymes or other ribonuclease-type complexes may be employed.
  • DNA gDNA, cDNA
  • RNA sense RNAs, antisense RNAs, niRNAs, tRNAs, rRNAs, small interfering RNAs (SiRNAs), short hairpin RNAs (ShRNAs), micro RNAs (miRNAs), small nucleolar RNAs (SnoRNAs, small nuclear (SnRNAs)) ribozymes, aptamers, DNAzymes or other
  • Agents in accordance with this aspect of the invention may directly interact with Erg.
  • small molecule antibodies or peptides, peptidomimetics or analogs and other such molecules may be conveniently employed.
  • genetic mechanisms are used to indirectly modulate the activity of Erg.
  • various strategies are well documented and include mechanisms for pre or post-transcriptional silencing.
  • the expression of antisense molecules or co-suppression or RNAi or siRNA strategies are particularly contemplated.
  • Agents which modulate the level or activity of Erg or Erg may be derived from Erg or Erg.
  • Natural products include those from coral, soil, plant, or the ocean or antarctic environments. Small molecule libraries are particularly convenient.
  • the agent to be tested is contacted with a system comprising Erg or Erg. Then, the following may be assayed for: the presence of a complex between the agent and Erg or Erg; a change in the interaction between Erg and a target; a change in the activity of the target, or a change in the level or activity of an indicator of the activity of the target.
  • Competitive binding assays and other high throughput screening methods are well known in the art and are described for example in International Publication Nos. WO 84/03564 and WO 97/02048).
  • all or part of the Erg gene promoter is operatively linked to a reporter construct and engineered into an expression construct as known to those of skill in the art.
  • a reporter construct for example, a pGL3-series reporter plasmid may be conveniently employed. Stable or transient transfection of cells may be used to generate cell lines capable of being tested with potential agents.
  • an Erg responsive cell line is generated comprising an inducible Erg gene.
  • Potential agents are tested for their ability to up-regulate or down-regulate expression differentiation markers when Erg is activated.
  • an Erg responsive cell line is the human cancer line K562 referred in Ceballos et ah, (Oncogene, 19:2194- 2204, 2000).
  • Ceballos et ah Ceballos et ah
  • morpholines may be used as described by Summerton et al, (Antisense and Nucleic Acid Drug Development 7:187-195, 1997).
  • Antisense molecules may interfere with any function of a nucleic acid molecule.
  • the functions of DNA to be interfered with can include replication and transcription. Replication and transcription, for example, can be from an endogenous cellular template, a vector, a plasmid construct or otherwise.
  • RNA to be interfered with can include functions such as translocation of the RNA to a site of protein translation, translocation of the RNA to sites within the cell which are distant from the site of RNA synthesis, translation of protein from the RNA, splicing of the RNA to yield one or more RNA species, and catalytic activity or complex formation involving the RNA which may be engaged in or facilitated by the RNA.
  • One preferred result of such interference with target nucleic acid function is modulation of the expression of the Erg gene.
  • antisense compound is a single-stranded antisense oligonucleotide
  • dsRNA double-stranded RNA
  • oligomeric compound refers to a polymer or oligomer comprising a plurality of monomeric units.
  • oligonucleotide refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics, chimeras, analogs and homologs thereof. This term includes oligonucleotides composed of naturally occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally occurring portions which function similarly.
  • modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for a target nucleic acid and increased stability in the presence of nucleases. While oligonucleotides are a preferred form of the compounds of this invention, the present invention comprehends other families of compounds as well, including but not limited to oligonucleotide analogs and mimetics such as those described herein.
  • the genetic agents or compositions in accordance with this invention preferably comprise from about 8 to about 80 nucleobases (i.e. from about 8 to about 80 linked nucleosides).
  • nucleobases i.e. from about 8 to about 80 linked nucleosides.
  • the invention embodies compounds of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 61, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 nucleobases in length.
  • the agents or compositions of the present invention may be Erg or parts thereof, or Erg or parts thereof or complementary forms or molecules derived or designed from Erg or Erg.
  • the present invention provides a composition comprising Erg or a functional variant or Erg or an agent from which either or these is producible which substantially enhances the activity of Erg.
  • the said composition effectively modulates hematopoietic cell level or activity such as enhancing stem cell or progenitor cell level or activity, platelet levels, red blood cell levels, white blood cell levels, immune cell levels such as macrophages and monocyte level or activity.
  • compositions and terms such as “agent”, “medicament”, “active” and “drug” are used interchangeably herein to refer to a chemical compound or cellular composition which induces a desired pharmacological and/or physiological effect.
  • the terms encompass pharmaceutically acceptable and pharmacologically active ingredients including but not limited to salts, esters, amides, pro-drugs, active metabolites, analogs and the like.
  • the term includes genetic and proteinaceous or lipid molecules or analogs thereof as well as cellular compositions as previously mentioned.
  • the instant compounds and compositions are suitable for the manufacture of a medicament for the treatment and/or prevention of conditions associates with early defects in blood cell development i.e. at the level of HSC and/or progenitor cell activity.
  • the present invention extends to cellular compositions including genetically modified stem cells which are capable of regenerating tissues and/or organs of an animal subject in situ or in vivo.
  • Stem cells or stem cell-like cells are preferably multipotent or pluripotent.
  • Other cellular compositions comprise vectors such as viral vectors for delivery of nucleic acid constructs as described later herein.
  • the terms “functional form” or “variant”, “functionally equivalent derivative” or “homolog” include molecules which selectively hybridize to Erg or a complementary form thereof over all or part of the genetic molecule under conditions of low or medium stringency at a defined temperature or range of conditions, or which have about 60% sequence identity to a nucleotide sequence encoding Erg polypeptides.
  • Exemplary Erg nucleotide sequences include those comprising nucleotide sequences set forth in SEQ ID NO: 1 (mouse Erg mRNA), SEQ ID NO: 3 (human Erg-1 mRNA) or SEQ ID NO: 5 (human Erg-2 mRNA) or their complements.
  • SEQ ID NO: 1 human Erg mRNA
  • SEQ ID NO: 3 human Erg-1 mRNA
  • SEQ ID NO: 5 human Erg-2 mRNA
  • Biological activity as determined herein includes enhancing hematopoietic stem cell and/or hematopoietic progenitor activity and potentiating transcription of transcriptional targets.
  • the terms functional form or variant, functionally equivalent derivatives or homologs include polypeptides comprising a sequence of amino acids having about 60% sequence identity to Erg.
  • Derivatives and variants are molecules which exhibit at least one biologically relevant function of the naturally occurring polypeptide such as DNA binding (such as via the ETS domain) or protein binding (such as via the pointer domain).
  • Exemplary Erg amino acid sequences include those comprising sequences set forth in SEQ ID NO: 2 (mouse Erg), SEQ ID NO: 4 (human Erg-1) and SEQ ID NO: 6 (human Erg-2).
  • low stringency includes and encompasses from at least about 0 to at least about 15% v/v formamide and from at least about 1 M to at least about 2 M salt for hybridization, and at least about 1 M to at least about 2 M salt for washing conditions.
  • low stringency is at from about 25-30°C to about 42°C. The temperature may be altered and higher temperatures used to replace formamide and/or to give alternative stringency conditions.
  • Alternative stringency conditions may be applied where necessary, such as "medium stringency", which includes and encompasses from at least about 16% v/v to at least about 30% v/v formamide and from at least about 0.5 M to at least about 0.9 M salt for hybridization, and at least about 0.5 M to at least about 0.9 M salt for washing conditions, or high stringency, which includes and encompasses from at least about 31% v/v to at least about 50% v/v formamide and from at least about 0.01 M to at least about 0.15 M salt for hybridization, and at least about 0.01 M to at least about 0.15 M salt for washing conditions.
  • T m of a duplex DNA decreases by I 0 C with every increase of 1% in the number of mismatch base pairs (Bonner et al, Eur. J. Biochem. 46: 83, 1974).
  • Formamide is optional in these hybridization conditions. Accordingly, particularly preferred levels of stringency are defined as follows: low stringency is 6 x SSC buffer, 0.1% w/v SDS at 25-42°C; a moderate stringency is 2 x SSC buffer, 0.1% w/v SDS at a temperature in the range 20°C to 65°C; high stringency is 0.1 x SSC buffer, 0.1% w/v SDS at a temperature of at least 65°C.
  • similarity includes exact identity between compared sequences at the nucleotide or amino acid level. Where there is non-identity at the nucleotide level, “similarity” includes differences between sequences which result in different amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. Where there is non-identity at the amino acid level, “similarity” includes amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. In a particularly preferred embodiment, nucleotide sequence comparisons are made at the level of identity and amino acid sequence comparisons are made at the level of similarity.
  • the precent similarity between a particular amino sequence and a reference sequence is at least about 65% or at least about 70% or at least about 80% or at least about 85% or more preferably at least about 90% similarity or above such as at least about 95%, 96%, 97%, 98%, 99% or greater. Percent similarities between 60 and 100% are encompassed.
  • the precent identity between a particular nucleotide sequence and a reference sequence is at least about 65% or at least about 70% or at least about 80% or at least about 85% or more preferably at least about 90% similarity or above such as at least about 95%, 96%, 97%, 98%, 99% or greater. Percent identities between 60 and 100% are encompassed.
  • a “reference sequence” is at least 12 but frequently 15 to 18 and often at least 25 or above, such as 30 monomer units, inclusive of nucleotides and amino acid residues, in length. Because two polynucleotides may each comprise (1) a sequence (i.e. only a portion of the complete polynucleotide sequence) that is similar between the two polynucleotides, and (2) a sequence that is divergent between the two polynucleotides, sequence comparisons between two (or more) polynucleotides are typically performed by comparing sequences of the two polynucleotides over a "comparison window" to identify and compare local regions of sequence similarity.
  • a “comparison window” refers to a conceptual segment of typically 12 contiguous residues that is compared to a reference sequence.
  • the comparison window may comprise additions or deletions (i.e. gaps) of about 20% or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences.
  • Optimal alignment of sequences for aligning a comparison window may be conducted by computerised implementations of algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Drive Madison, WI, USA) or by inspection and the best alignment (i.e. resulting in the highest percentage homology over the comparison window) generated by any of the various methods selected.
  • a percentage of sequence identity between nucleotide sequences is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g. A, T, C,
  • sequence identity will be understood to mean the "match percentage” calculated by the DNASIS computer program (Version 2.5 for windows; available from Hitachi Software engineering
  • derivatives or the plural “derivatives” whether in relation to genetic or proteinaceous molecules includes, as appropriate, parts, mutants, fragments, and analogues as well as hybrid, chimeric or fusion molecules and glycosylation variants. Particularly useful derivatives retain at least one functional activity of the parent molecule and comprise single or multiple amino acid substitutions, deletions and/or additions to the Erg amino acid sequence. Preferably, the derivatives have functional activity or alternatively, modulate Erg functional activity.
  • modulate includes up modulate or up- regulate and down-modulate or down-regulate.
  • portion or fragment of Erg is defined as having a minimal size of at least about 10 nucleotides or preferably about 13 nucleotides or more preferably at least about 20 nucleotides , and may have a minimal size of at least about 35 nucleotides.
  • This definition includes all sizes in the range of 10 to 35 as well as greater than 35 nucleotides.
  • this definition includes nucleic acids of 12, 15, 20, 25, 40, 60, 100, 200, 500 nucleotides of nucleic acid molecules having any number of nucleotides between 500 and the number shown in SEQ ID NO: 1, SEQ ID NO:3 or SEQ ID NO: 5 or a complementary form thereof.
  • SEQ ID NO: 1 SEQ ID NO:3
  • SEQ ID NO: 5 or a complementary form thereof.
  • Substitutional variants typically contain the exchange of one amino acid for another at one or more sites within the protein and may be designed to modulate one or more properties of the polypeptide such as stability against proteolytic cleavage without the loss of other functions or properties.
  • Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of the residues involved.
  • Preferred substitutions are ones which are conservative, that is, one amino acid is replaced with one of similar shape and charge.
  • Conservative substitutions are well known in the art and typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and tyrosine, phenylalanine (see Table 3).
  • Certain amino acids may be substituted for other amino acids in a protein structure without appreciable loss of interactive binding capacity with structures such as, for example, antigen-binding regions of antibodies or binding sites on substrate molecules or binding sites on proteins interacting with the Erg polypeptide.
  • homolog or “homologs” refers herein broadly to functionally and/or structurally related molecules including those from other species.
  • peptide mimetic includes nucleic acid or peptide mimetics and it intended to refer to a substance which has conformational features allowing the substance to perform as a functional analog.
  • a peptide mimetic may be peptide containing molecules that mimic elements of protein secondary structure (Johnson et al "Peptide Turn Mimetics” in Biotechnology and Pharmacy, Pezzuto et al eds Chapman and Hall, New York, 1993).
  • Peptide mimetics may be identified by screening random peptide libraries such as phage display libraries for peptide molecules which mimic the functional activity of Erg. Alternatively, mimetic design, synthesis and testing are employed.
  • Nucleic acid mimetics include, for example, RNA analogs containing N3' ⁇ P5' phosphoramidate internucleotide linkages which replace the naturally occurring RNA 03'-- P5' phosphodiester groups.
  • Enzyme mimetics include catalytic antibodies or their encoding sequences, which may also be humanised.
  • Peptide or non-peptide mimetics can be developed as functional analogues of Erg by identifying those residues of the target molecule which are important for function. Modelling can be used to design molecules which interact with the target molecule and which have improved pharmacological properties. Rational drug design permits the production of structural analogs of biologically active polypeptides of interest or of small molecules with which they interact (e.g. agonists, antagonists, inhibitors or enhancers) in order to fashion drugs which are, for example, more active or stable forms of the polypeptide, or which, e.g. enhance or interfere with the function of a polypeptide in vivo. See, e.g. Hodgson ⁇ Bio/Technology, 9: 19-21, 1991).
  • Useful information regarding the structure of a polypeptide may also be gained by modelling based on the structure of homologous proteins.
  • An example of rational drug design is the development of HIV protease inhibitors (Erickson et al, Science 249:527-533, 1990).
  • target molecules may be analyzed by an alanine scan (Wells, Methods Enzymol, 202:2699-2705, 1991).
  • an amino acid residue is replaced by Ala and its effect on the peptide's activity is determined.
  • Each of the amino acid residues of the peptide is analyzed in this manner to determine the important regions of the peptide.
  • a target-specific antibody selected by a functional assay and then to solve its crystal structure.
  • this approach yields a pharmacore upon which subsequent drug design can be based. It is possible to bypass protein crystallography altogether by generating anti-idiotypic antibodies (anti-ids) to a functional, pharmacologically active antibody. As a mirror image of a mirror image, the binding site of the anti-ids would be expected to be an analog of the original receptor. The anti-id could then be used to identify and isolate peptides from banks of chemically or biologically produced banks of peptides. Selected peptides would then act as the pharmacore. As briefly described, it is possible to design or screen for mimetics which have enhanced activity or stability or are more readily and/or more economically obtained.
  • Analogs of Erg or other agents described herein preferably have enhanced stability and activity. They may also be designed in order to have an enhanced ability to cross biological membranes or to interact with only specific substrates. Thus, analogs may retain some functional attributes of the parent molecule but may posses a modified specificity or be able to perform new functions useful in the present context i.e., for administration to the nucleus, bone marrow, etc.
  • Analogs contemplated herein include but are not limited to modification to side chains, incorporating of unnatural amino acids and/or their derivatives during peptide, polypeptide or protein synthesis and the use of crosslinkers and other methods which impose conformational constraints on the proteinaceous molecule or their analogs.
  • side chain modifications contemplated by the present invention include modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH 4 ; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5-phosphate followed by reduction with NaBH 4 .
  • modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH 4 ; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS);
  • the guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.
  • the carboxyl group may be modified by carbodiimide activation via O-acylisourea formation followed by subsequent derivitization, for example, to a corresponding amide.
  • Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4- chloromercuribenzoate, 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2- chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH.
  • Tryptophan residues may be modified by, for example, oxidation with N- bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides.
  • Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.
  • Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethylpyrocarbonate .
  • Examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3- hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or D-isomers of amino acids.
  • a list of unnatural amino acid, contemplated herein is shown in Table 4.
  • peptides can be conformationally constrained by, for example, incorporation of C ⁇ and N ⁇ -methylamino acids and the introduction of double bonds between C ⁇ and Cp atoms of amino acids.
  • the small or large chemicals, polypeptides, nucleic acids, antibodies, peptides, chemical analogs, or mimetics of the present invention can be formulated in pharmaceutic compositions which are prepared according to conventional pharmaceutical compounding techniques. See, for example, Remington's Pharmaceutical Sciences, (20th ed. Williams and Wilkins (2000)).
  • the composition may contain the active agent or pharmaceutically acceptable salts of the active agent.
  • These compositions may comprise, in addition to one of the active substances, a pharmaceutically acceptable excipient, carrier, buffer, stabilizer or other materials well known in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g.
  • compositions comprising an active agent which modulates the activity of Erg or its transcriptional targets for use or when used in modulating hematopoietic cell activity as defined herein.
  • an active agent which modulates the activity of Erg or its transcriptional targets for use or when used in modulating hematopoietic cell activity as defined herein.
  • the use of the herein described agent is expressly contemplated in the manufacture of a medicament for the treatment of conditions associated with HSC defects associated with Erg variants.
  • the subject is tested for Erg variants prior to administration.
  • the compounds can be formulated into solid or liquid preparations such as capsules, pills, tablets, lozenges, powders, suspensions or emulsions.
  • any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, suspending agents, and the like in the case of oral liquid preparations (such as, for example, suspensions, elixirs and solutions); or carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations (such as, for example, powders, capsules and tablets).
  • tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar-coated or enteric-coated by standard techniques.
  • the active agent can be encapsulated to make it stable to passage through the gastrointestinal tract while at the same time allowing for passage across the blood brain barrier. See for example, International Patent Publication No. WO 96/11698.
  • the compound may dissolved in a pharmaceutical carrier and administered as either a solution or a suspension.
  • suitable carriers are water, saline, dextrose solutions, fructose solutions, ethanol, or oils of animal, vegetative or synthetic origin.
  • the carrier may also contain other ingredients, for example, preservatives, suspending agents, solubilizing agents, buffers and the like.
  • the compounds When the compounds are being administered intrathecally, they may also be dissolved in cerebrospinal fluid.
  • the active agent is preferably administered in a therapeutically effective amount.
  • the actual amount administered and the rate and time-course of administration will depend on the nature and severity of the condition being treated. Prescription of treatment, e.g. decisions on dosage, timing, etc. is within the responsibility of general practitioners or specialists and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of techniques and protocols can be found in Remington's Pharmaceutical Sciences, 2000 ⁇ supra).
  • targeting therapies may be used to deliver the active agent more specifically to certain types of cell, by the use of targeting systems such as antibodies or cell specific ligands. Targeting may be desirable for a variety of reasons, e.g. if the agent is unacceptably toxic or if it would otherwise require too high a dosage or if it would not otherwise be able to enter the target cells.
  • the vector could be targeted to the target cells or expression of expression products could be limited to specific cells, stages of decelopment or cell cycle stages.
  • the cell based delivery system is designed to be implanted in a patient's body at the desired target site and contains a coding sequence for the target agent.
  • the agent could be administered in a precursor form for conversion to the active form by an activating agent produced in, or targeted to, the cells to be treated. See, for example, European Patent Application No. 0 425 73 IA and International Patent Publication No. WO 90/07936.
  • expression constructs are produced comprising all or part of Erg nucleic acid sequences as described herein or variants thereof as described herein.
  • the cells of a subject may be tested to determine whether gene or cell therapy with an agent comprising Erg is indicated.
  • the provision of wild type or enhanced Erg function to a cell which carries a mutant or altered form of Erg should in this situation complement the deficiency and result in an improvement in the subject.
  • cells capable of providing normal or enhanced Erg function may be provided.
  • the Erg allele may be introduced into a cell in a vector such that the gene remains extrachromosomally.
  • artificial chromosomes may be used.
  • the vector may combine with the host genome and be expressed therefrom.
  • Gene therapy would be carried out according to generally accepted methods, for example, as described by Friedman (In: Therapy for Genetic Disease, T. Friedman, Ed., Oxford University Press, pp. 105-121, 1991) or Culver (Gene Therapy: A Primer for Physicians, 2 nd Ed., Mary Ann Liebert, 1996).
  • Suitable vectors are known, such as disclosed in U.S. Patent No. 5,252,479, International Patent Publication No. WO 93/07282 and U.S. Patent No. 5,691,198.
  • Gene transfer systems known in the art may be useful in the practice of the gene therapy methods of the present invention. These include viral and non-viral transfer methods as well known in the art.
  • Non-viral gene transfer methods are also known in the art such as chemical techniques including calcium phosphate co-precipitation, mechanical techniques, for example, microinjection, membrane fusion-mediated transfer via liposomes and direct DNA uptake and receptor-mediated DNA transfer.
  • chemical techniques including calcium phosphate co-precipitation, mechanical techniques, for example, microinjection, membrane fusion-mediated transfer via liposomes and direct DNA uptake and receptor-mediated DNA transfer.
  • Viral-mediated gene transfer can be combined with direct in vivo gene transfer using liposome delivery.
  • plasmid DNA of any size is combined with a polylysine-conjugated antibody specific to the adenovirus hexon protein and the resulting complex is bound to an adenovirus vector.
  • the trimolecular complex is then used to infect cells.
  • the adenovirus vector permits efficient binding, internalization and degradation of the endosome before the coupled DNA is damaged.
  • Liposome/DNA complexes are also capable of mediating direct in vivo gene transfer.
  • Expression vectors in the context of gene therapy are meant to include those constructs containing sequences sufficient to express a polynucleotide that has been cloned therein.
  • the construct contains viral sequences sufficient to support packaging of the construct. If the polynucleotide encodes Erg, expression will produce Erg.
  • polynucleotide encodes a sense or antisense polynucleotide or a ribozyme
  • DNAzyme expression will produce the sense or antisense polynucleotide or ribozyme or DNAzyme. Thus, in this context, expression does not require that a protein product be synthesized.
  • the vector also contains a promoter functional in eukaryotic cells. The cloned polynucleotide sequence is under control of this promoter. Suitable eukaryotic promoters are routinely determined. Receptor-mediated gene transfer may be achieved by conjugation of DNA to a protein ligand via polylysine. Ligands are chosen on the basis of the presence of the corresponding ligand receptors on the cell surface of the target cell/tissue type.
  • ligand-DNA conjugates can be injected directly into the blood if desired and are directed to the target tissue where receptor binding and internalization of the DNA-protein complex occurs.
  • co-infection with adenovirus can be included to disrupt endosome function.
  • patients who carry an aberrant Erg allele are treated with a gene delivery vehicle such that some or all of their cells receive at least one additional copy of a functional normal Erg allele. Preferably only specific cells are targeted.
  • peptides or mimetics or other functional analogues which have Erg activity can be supplied to cells which carry aberrant Erg alleles.
  • Protein can be produced by expression of the cDNA sequence in bacteria, for example, using known expression vectors.
  • synthetic chemistry techniques can be employed to synthesize the instant active molecules. Active molecules can be introduced into cells by microinjection or by use of liposomes, for example. Alternatively, some active molecules may be taken up by cells, actively or by diffusion. In some embodiments, supply of molecules with Erg activity should lead to enhanced blood cell function, enhanced HSC and/or progenitor cell activity.
  • Scanning methods include sequencing, denaturing gradient gel electrophoresis (DGGE), single-stranded conformational polymorphism (SSCP and rSSCP, REF-SSCP) 5 chemical cleavage methods such as CCM, ECM, DHPLC and MALDI-TOF MS and DNA chip technology.
  • DGGE denaturing gradient gel electrophoresis
  • SSCP and rSSCP single-stranded conformational polymorphism
  • REF-SSCP REF-SSCP
  • the present invention provides methods of diagnosis of conditions associated with modified Erg and further provides genetic or protein based methods of determining the susceptibility of a subject to develop these conditions.
  • the diagnostic and prognostic methods of the present invention detect or assess an aberration in the wild type Erg gene or locus to determine if Erg will be produced or if it will be over-produced or under-produced.
  • the term "aberration" in the Erg gene or locus encompasses all forms of mutations including deletions, insertions, point mutations and substitutions in the coding and non-coding regions of Erg. It also includes changes in methylation patterns of Erg or of an allele of Erg. Deletions may be of the entire gene or only a portion of the gene. Point mutations may result in stop codons, frameshift mutations or amino acid substitutions. Somatic mutations are those which occur only in certain tissues, e.g.
  • Germline mutations can be found in any of a body's tissues and are inherited.
  • An Erg allele which is not deleted e.g. that found on the sister chromosome to a chromosome carrying a Erg deletion
  • can be screened for other mutations such as insertions, small deletions, point mutations and changes in methylation pattern. It is considered in accordance with the present invention that many mutations found in cells such as hepatic cells are those leading to decreased or increased expression of the Erg gene.
  • Useful diagnostic techniques to detect aberrations in the Erg gene include but are not limited to fluorescent in situ hybridization (FISH), direct DNA sequencing, PFGE analysis, Southern blot analysis, single-stranded coformational analysis (SSCA), Rnase protection assay, allele-specific oligonucleotide (ASO hybridization), dot blot analysis and PCR- SSCP (see below). Also useful is DNA microchip technology.
  • Predisposition to conditions associated with stem cell defects can be ascertained by testing any tissue of a human or other mammal for mutations in a Erg gene. This can be determined by testing DNA from any tissue of a subject's body. In addition, pre-natal diagnosis can be accomplished by testing fetal cells, placental cells or amniotic fluid for mutations of the Erg gene. Alteration of a wild type allele whether, for example, by point mutation or by deletion or by methylation, can be detected by any number of means.
  • SSCP single-stranded conformation polymorphism assay
  • CDGE clamped denaturing gel electrophoresis
  • HA heteroduplex analysis
  • CMC chemical mismatch cleavage
  • Other methods which might detect mutations in regulatory regions or which might comprise large deletions, duplications or insertions include the protein truncation assay or the asymmetric assay.
  • SSCA single-stranded conformation analysis
  • DGGE denaturing gradient gel electrophoresis
  • primers are used which hybridize at their 3' ends to a particular Erg mutation or to junctions of DNA caused by a deletion of Erg. If the particular Erg mutation is not present, an amplification product is not observed.
  • Amplification Refractory Mutation System (ARMS) can also be used, as disclosed in European Patent Publication No. 0 332 435 and in Newtown et al ⁇ Nucl Acids. Res., 77:2503-2516, 1989). Insertions and deletions of genes can also be detected by cloning, sequencing and amplification.
  • Microchip technology is also applicable to the present invention.
  • thousands of distinct oligonucleotide or cDNA probes are built up in an array on a silicon chip or other solid support such as polymer films and glass slides.
  • Nucleic acid to be analyzed is labelled with a reporter molecule (e.g. fluorescent label) and hybridized to the probes on the chip.
  • reporter molecule e.g. fluorescent label
  • the technique is described in a range of publications including Hacia et al.
  • Alteration of wild type Erg genes can also be detected by screening for alteration of wild type Erg proteins.
  • monoclonal antibodies immunoreactive with Erg can be used to screen a tissue. Lack of cognate antigen would indicate an Erg mutation.
  • Antibodies specific for products of mutant alleles could also be used to detect mutant Erg gene product.
  • immunological assays can be done in any convenient format known in the art. These include Western blots, immunohistochemical assays and ELISA assays.
  • the use of monoclonal antibodies in an immunoassay is particularly preferred because of the ability to produce them in large quantities and the homogeneity of the product.
  • the preparation of hybridoma cell lines for monoclonal antibody production is derived by fusing an immortal cell line and lymphocytes sensitized against the immunogenic preparation (i.e. comprising Erg) or can be done by techniques which are well known to those who are skilled in the art. (See, for example, Douillard and Hoffman, Basic Facts about Hybridomas, in Compendium of Immunology Vol. II, ed. by Schwartz, 1981; Kohler et al, Nature, 256:495-499, 1975; Kohler et al, European Journal of Immunology. (5:511- 519, 1976).
  • primers used to amplify regions of Erg genetic sequence are routinely derived by the skilled addressee based on known sequences for Erg.
  • MpI ' ' ' C57BL/6 mice were injected with ENU as described previously and bred with isogenic females (Carpinelli et al, Proc. Natl. Acad. Sci. TJ. S. A., 207:6553-6558, 2004). Blood was taken from their progeny at 7 weeks and analysed on an automated hematological analyser. One mouse had low numbers of RBCs, WBCs and platelets relative to MpV 1' mice. The mutation was responsible for this multilineage defect was designated mld2 ( Figure 1).
  • mice are anaemic, leukopenic, thrombocytopenic and have reduced survival on a MpT f" genetic background
  • the mld2/+ MpV 1' founder mouse was mated to +/+ MpV 1" mice to further investigate the mld2 phenotype and its inheritance.
  • the progeny were bled at seven weeks.
  • the RBC counts of these progeny split into two clearly demarcated populations and genotypes were inferred on this basis (mld2/+ MpV 1" for RBC ⁇ 8.0 per pL, +/+ MpI ' ' ' for RBC > 8.0 per pL, Figure 2).
  • the mld2/+ MpV 1' mice have an approximately 47% deficiency in RBCs.
  • mld2/+ MpV 1 also appear to have deficiencies in all lineages of leukocytes (54% deficient overall) as well as platelets (80% deficient, Figure 2).
  • leukocytes 54% deficient overall
  • platelets 80% deficient, Figure 2.
  • mice In addition to this multilineage deficiency, mld2/+ MpV 1' mice also showed decreased survival (Figure 3). As above, this data is based on genotypes inferred from RBC counts. None of the 13 mld2/+ MpV 1' progeny of the original mouse identified in the screen survived longer than 205 days, and only one survived longer than 110 days, before succumbing to illness. Preliminary data from post mortem analyses suggests that this illness is associated with internal haemorrhaging under the skin, around the joints and in the skull. Conversely, none of the +/+ MpT 1' littermates became ill. Preliminary data from accurately genotyped mice supports this data.
  • a more comprehensive survival and pathology experiment is performed with a dedicated cohort of un-manipulated mice.
  • a dominant lethal phenotype makes maintaining a colony difficult, however the original mouse identified in the screen bred, and sperm was frozen from an additional affected male.
  • the mldl lethality is dependent on a MpI "7" phenotype (see below), and thus a colony of mice carrying the mldl mutation in the absence of lethal disease is maintained.
  • mld2/+ MpV 1' marrow was able to make only negligible contributions to hematopoiesis (2.1% and 1.2% of mature blood cells were derived from the two m ⁇ d2/+ MpT 1" donors) compared to a 22.4% contribution by +/+ MpT 1" test marrow.
  • mice have a severe deficiency of HSCs and/or multipotential progenitor activity. More experiments will be performed to determine whether this is due to deficient numbers, functional activity or homing.
  • Transplantation studies will be undertaken incorporating analysis of purified HSCs, as well as a full analysis of hematopoietic precursor cells, and semi-solid culture assays. These will confirm the effect of mld2 on the activity of HSCs, multipotent progenitors and lineage committed progenitors.
  • EXAMPLE 4 The mld2 mutation exists in a 1.6 megabase interval on chromosome 16
  • the mld2 mutation was localized using the same principles as for mld3 (see above). Briefly, mld2/+ MpT 1' C57BL/6 mice were crossed to wild type Balb/c mice. The G 1 progeny were then crossed to +/+ MpT 1' C57BL/6 mice. Therefore, in the resultant G 2 mice, the genotypes of the genetic markers nearest to the mld2 mutation will be homozygous C57BL/6 in all mice carrying mld2, and conversely they will be heterozygous in those not carrying it. The mld2 mutation can be localised by finding the smallest region of markers for which this remains true.
  • mice heterozygous for the mld2 mutation varies with the presence of functional c-Mpl
  • mice homozygous for the mld2 mutation G 1 mice from the mapping cross, which were mld2/+ Mpf " , were mated to one another. Because of the mixed background of these mice, their mld2 genotype could be determined by SSLP genotyping of genetic markers surrounding the vicinity of the mld2 mutation. Of 51 such progeny, genotyped at weaning, none carried two copies of the mld2 mutation, although -13 were expected to (Table 6). Instead, the ratio of genotypes is similar to that predicted if the mld2/mld2 genotype is assumed to be lethal.
  • the mld2/mld2 genotype appears to be lethal regardless of the MpI genotype (data not shown). Presumably the mld2/mld2 mice are dying as embryos. The stage at which the embryos are dying is determined, and attempt to determine the cause of death, with a particular focus on hematopoietic defects.
  • the mld2 mutation causes a serine to proline substitution in the DNA binding domain of the ETS transcription factor Erg.
  • the 1.6 megabase interval known to contain the mld2 mutation contained 8 genes.
  • One of these genes is the ETS transcription factor Erg.
  • Erg was identified as a strong candidate gene to carry the mld2 mutation.
  • the coding exons and intron-exon boundaries of Erg were sequenced.
  • a T to C nucleotide substitution was identified in exon 12 of Erg in all mld2/+ mice, but in no +/+ mice ( Figure 5). This causes a serine to proline substitution in the ETS domain of Erg.
  • This mutation lies immediately distal to an alpha helix highly conserved amongst the 26 ETS family genes in the mouse, and so may be predicted to disrupt the function of this DNA binding domain.
  • the mld2 gene and wild type Erg cDNA are cloned using standard procedure (Ausubel). Whether the mld2 mutation prevents DNA binding will be determined using electrophoretic mobility shift assays. The effect of the mutation on function will be determined using reporter gene assays and biological assays such as the ability to induce megakaryocytic differentiation of K562 cells.
  • the mld2 multilineage phenotype will be correcting through the infection of wild type or mutant bone marrow with wild type or mutant Erg, or through the expression of wild type or mutant Erg in transgenic mice.
  • Erg is a transcription factor, it functions by modulating the expression of other genes.
  • the mechanism by which the disruption of Erg by mld2 causes the mld2 phenotype, will be investigated by defining the target genes of Erg that are critical to the mld2 phenotype. This is achieved using techniques such as chromatin immunoprecipitation and microarrays.
  • the targets of Erg are themselves regulators of hematopoiesis, including HSCs and multipotent progenitor function.
  • the mld2/+ MpI " mice model system is used to determine the function of candidate hematopoietic regulators and their variants.
  • Erg regulates the expression of hematopoietic signally molecules such as cytokine, hormone and chemokine.
  • the signalling molecules or their cellular or nuclear receptors are expressed early in hematopoiesis.
  • Exemplary molecules include thrombopoietin and/or MpI and/or ScI.
  • the expression profile of normal hematopoietic cells, and cells that carry the mld2 mutation in Erg are compared, for example, by microarray analysis.
  • interesting genes implicated in the Erg pathway are confirmed by real-time RT-PCR and followed up in vivo by transgenic and knockout mouse approaches.
  • Another method uses genome-wide mapping of protein-DNA interactions by chromatin immunoprecipitation and DNA microarray hybridisation (ChIP-on-Chip) sequence location analyses. Chromatin immunoprecipitation (ChIP) using an antibody to Erg separates Erg from a cell lysate together with nucleic acid sequences to which Erg is bound.
  • the sequence of the bound nucleic acids can be determined and how often they are represented in the cell lysate. This indicates the gene promoters to which Erg binds in a given cell, and therefore, its transcriptional targets.
  • ENU mutagenesis modifier screen are performed i.e. a screen for mutations that can enhance or suppress the phenotypes caused by mld2 Erg mutation in Erg.
  • This will identify two classes of genes: 1) those that act within the Erg pathway, and 2) genes that act outside the Erg pathway, but which when mutated, produce biologic effects that can enhance or suppress that induced by mutations in Erg.
  • the present invention therefore also contemplated modified animals comprising two or more different mutations the Erg signalling pathway or its transcriptional targets.
  • class 2) genes which when mutated suppresses the mld2/+ phenotype are further targets for the development of agents useful in the present invention.
  • Non-conventional Code Non-conventional Code amino acid amino acid
  • Test Competitor Endogenous mld2/+ MpT ' mouse 1 2. 1 ⁇ 1.3 68.9 ⁇ 7.5 28.4 ⁇ 6.3 mld2/+ MpT f" mouse 2 1. 2 ⁇ 0.4 68.5 ⁇ 12.8 29.2 ⁇ 11.6
  • Sorensen et ⁇ /., /V ⁇ t. Genet (5:146-151, 1994. Summerton et al, Antisense and Nucleic Acid Drug Development 7: 187- 195, 1997.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des procédés de modulation de l'activité des cellules hématopoïétiques comprenant la modulation du taux ou de l'activité d'un polypeptide de gène ets (Erg) ou d'une cible transcriptionnelle d'un polypeptide Erg ou d'un effecteur en aval de l'activité du polypeptide Erg. Les cellules hématopoïétiques comprennent également les érythrocytes et les leucocytes. De plus, les cellules hématopoïétiques comprennent les cellules souches hématopoïétiques (HSC) et les cellules précurseur hématopoïétiques. L'activité des cellules hématopoïétiques compte au moins une fonction impliquant la domiciliation, le greffage, la survie, l'autorenouvellement et la différenciation. Par ailleurs, l'invention concerne des procédés de criblage de modulateurs de l'activité des cellules hématopoïétiques, notamment de modulateurs qui reposent entre autres choses sur le blocage du gène Erg ou sur l'administration de séquences de codage du polypeptide Erg.
PCT/AU2007/000645 2006-05-12 2007-05-14 HÉMATOPOÏÈSE: RÉGULATION PAR UN GÈNE ETS (Erg) Ceased WO2007131280A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2006902556A AU2006902556A0 (en) 2006-05-12 Hematopoiesis and regulation thereof
AU2006902556 2006-05-12

Publications (1)

Publication Number Publication Date
WO2007131280A1 true WO2007131280A1 (fr) 2007-11-22

Family

ID=38693449

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2007/000645 Ceased WO2007131280A1 (fr) 2006-05-12 2007-05-14 HÉMATOPOÏÈSE: RÉGULATION PAR UN GÈNE ETS (Erg)

Country Status (1)

Country Link
WO (1) WO2007131280A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009105335A1 (fr) * 2008-02-22 2009-08-27 St.Jude Children's Research Hospital Méthodes et compositions pour le diagnostic et le traitement de la leucémie lymphoblastique aiguë
CN118711805A (zh) * 2024-08-30 2024-09-27 吉林大学 血液疾病智能诊疗辅助系统及方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001088124A2 (fr) * 2000-05-16 2001-11-22 Ribozyme Pharmaceuticals, Inc. Procede et reactif destine a l'inhibition d'erg

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001088124A2 (fr) * 2000-05-16 2001-11-22 Ribozyme Pharmaceuticals, Inc. Procede et reactif destine a l'inhibition d'erg

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANDERSON M.K. ET AL.: "Precise developmental regulation of Ets family transcription factors during specification and commitment to the T cell lineage", DEVELOPMENT, vol. 126, no. 14, June 1999 (1999-06-01), pages 3131 - 3148 *
DERAMAUDT T.B. ET AL.: "Identification of interaction partners for two closely-related members of the ETS protein family, FLI and ERG", GENE, vol. 274, no. 1-2, 22 August 2001 (2001-08-22), pages 169 - 177 *
HART A.H. ET AL.: "Human ERG is a proto-oncogene with mitogenic and transforming activity", ONCOGENE, vol. 10, no. 7, 6 April 1995 (1995-04-06), pages 1423 - 1430 *
MARCUCCI G. ET AL.: "Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study", J. CLIN. ONCOL., vol. 23, no. 36, 20 December 2005 (2005-12-20), pages 9234 - 9242 *
MCLAUGHLIN F.L. ET AL.: "Combined genomic and antisense analysis reveals that the transcription factor Erg is implicated in endothelial cell differentiation", BLOOD, vol. 98, no. 12, 1 December 2001 (2001-12-01), pages 3332 - 3339 *
PEREIRA D.S. ET AL.: "Retroviral transduction of TLS-ERG initiates a leukemogenic program in normal human hematopoietic cells", PROC. NATL. ACAD. SCI. U.S.A., vol. 95, no. 14, 7 July 1998 (1998-07-07), pages 8239 - 8244 *
RAINIS L. ET AL.: "The proto-oncogene ERG in megakaryoblastic leukemias", CANCER RES., vol. 165, no. 17, 1 September 2005 (2005-09-01), pages 7596 - 7602 *
YANG L. ET AL.: "Molecular cloning of ESET, a novel histone H3-specific methyltransferase that interacts with ERG transcription factor", ONCOGENE, vol. 21, no. 1, 3 January 2002 (2002-01-03), pages 148 - 152 *
YI H. ET AL.: "Inhibition of apoptosis by normal and aberrant Fli-1 and erg proteins involved in human solid tumors and leukemias", ONCOGENE, vol. 14, no. 11, 20 March 1997 (1997-03-20), pages 1259 - 1268 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009105335A1 (fr) * 2008-02-22 2009-08-27 St.Jude Children's Research Hospital Méthodes et compositions pour le diagnostic et le traitement de la leucémie lymphoblastique aiguë
CN118711805A (zh) * 2024-08-30 2024-09-27 吉林大学 血液疾病智能诊疗辅助系统及方法

Similar Documents

Publication Publication Date Title
US20100292200A1 (en) Methods for Modulating Apoptosis in Platelets
WO2008025069A1 (fr) Procédés de modulation de l'activité cellulaire et compositions à cet effet
EP0948522B1 (fr) Agents therapeutiques et diagnostiques capables de moduler la receptivite cellulaire aux cytokines
US20070135336A1 (en) Follistatin isoforms and uses thereof
EP0931149B1 (fr) Nouveau recepteur d'hematopoietine et sequences genetiques codant ce dernier
WO2010022444A1 (fr) Procédés et agents pour moduler des voies de signalisation de kinase par modulation de protéine de type domaine kinase de lignage mixte (mlkl)
WO2008017123A1 (fr) Procédés de modulation de l'apoptose dans les plaquettes
US7049418B2 (en) Therapeutic and diagnostic agents comprising a SOCS box
WO1998009510A1 (fr) Methodes diagnostiques et therapeutiques en matiere de cancer
US20090077677A1 (en) Mammalian grainyhead transcription factors
WO2007131280A1 (fr) HÉMATOPOÏÈSE: RÉGULATION PAR UN GÈNE ETS (Erg)
WO2010037181A1 (fr) Thérapie cellulaire et préparations à cet effet
WO2006105602A1 (fr) Modeles animaux et cellules dotees d’un gene modifie codant pour une proteine associee a la transthyretine et applications de ceux-ci
EP1242111B1 (fr) Modele animal d'etude de la signalisation hormonale et procede de modulation de cette signalisation
EP1723235B1 (fr) Cellules modifiees co-exprimant blimp1 et molecule rapportrice et procedes d'utilisation de celles-ci
WO2004080478A1 (fr) Compositions therapeutiques et prophylactiques et leurs utilisations
WO2010019995A1 (fr) Modulation du développement vasculaire par le facteur de transcription erg
US20070275916A1 (en) Methods of Identifying Compounds Which Modulate Granulocite-Colony Stimulating Factor (G-Csf) Dependent Processes by Modulation of the Levels of Suppressor of Cytokine Signaling (Socs)
AU2008207400A1 (en) Developmental Protocols
US7279557B2 (en) Therapeutic and diagnostic agents
WO2003066869A1 (fr) Gene suppresseur de tumeur lmt
US7220828B2 (en) Haemopoietin receptor and genetic sequence encoding same
WO2011137486A1 (fr) Méthodes de diagnostic et de pronostic et thérapeutiques
WO1999050410A1 (fr) Nouvelles molecules exprimees lors du developpement musculaire et sequences genetiques codant ces dernieres
EP1661577A1 (fr) Preparation therapeutique destinee aux maladies hematopoietiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07718891

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07718891

Country of ref document: EP

Kind code of ref document: A1